- Home
- ACHL vs ALVR Comparison
ACHL vs ALVR Comparison
Compare ACHL & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- ALVR
- Stock Information
- Founded
- ACHL 2016
- ALVR 2013
- Country
- ACHL United Kingdom
- ALVR United States
- Employees
- ACHL N/A
- ALVR N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHL Health Care
- ALVR Health Care
- Exchange
- ACHL Nasdaq
- ALVR Nasdaq
- Market Cap
- ACHL 43.6M
- ALVR 52.2M
- IPO Year
- ACHL 2021
- ALVR 2020
- Fundamental
- Price
- ACHL $0.95
- ALVR $0.45
- Analyst Decision
- ACHL Buy
- ALVR Sell
- Analyst Count
- ACHL 2
- ALVR 5
- Target Price
- ACHL $4.00
- ALVR $1.00
- AVG Volume (30 Days)
- ACHL 107.8K
- ALVR 340.7K
- Earning Date
- ACHL 11-14-2024
- ALVR 11-12-2024
- Dividend Yield
- ACHL N/A
- ALVR N/A
- EPS Growth
- ACHL N/A
- ALVR N/A
- EPS
- ACHL N/A
- ALVR N/A
- Revenue
- ACHL N/A
- ALVR N/A
- Revenue This Year
- ACHL N/A
- ALVR N/A
- Revenue Next Year
- ACHL N/A
- ALVR N/A
- P/E Ratio
- ACHL N/A
- ALVR N/A
- Revenue Growth
- ACHL N/A
- ALVR N/A
- 52 Week Low
- ACHL $0.63
- ALVR $0.40
- 52 Week High
- ACHL $1.76
- ALVR $2.42
- Technical
- Relative Strength Index (RSI)
- ACHL 29.24
- ALVR 31.87
- Support Level
- ACHL $0.97
- ALVR $0.40
- Resistance Level
- ACHL $1.01
- ALVR $0.53
- Average True Range (ATR)
- ACHL 0.03
- ALVR 0.04
- MACD
- ACHL -0.01
- ALVR 0.00
- Stochastic Oscillator
- ACHL 0.87
- ALVR 27.34
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.